The antimicrobial susceptibility of non-tuberculous mycobacteria

Journal of Infection

Volumn 72, Issue 3, 2016, Pages 324-331

  Cowman, S ^a,b   Burns, K ^a   Benson, S ^a   Wilson, R ^a,b   Loebinger, M R ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti mycobacterial agents; Antimicrobial drug resistance; Mycobacteriaceae; Non tuberculous mycobacteria

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; FUSIDIC ACID; GENTAMICIN; ISONIAZID; KANAMYCIN; LINEZOLID; MEROPENEM; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM XENOPEI; NONHUMAN; RETROSPECTIVE STUDY; TREND STUDY; ADOLESCENT; ADULT; AGED; BACTERIAL PNEUMONIA; CHILD; DRUG EFFECTS; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIOSIS; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; NONTUBERCULOUS MYCOBACTERIA; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84958158677     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.12.007     Document Type: Article

References (46)

1. Falkinham J. Ecology of nontuberculous mycobacteria-where do human infections come from?. Semin Respir Crit Care Med 2013, 34:95-102.
2. Prince D.S., Peterson D.D., Steiner R.M., Gottlieb J.E., Scott R., Israel H.L., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989, 321:863-868.
3. Adjemian J., Olivier K.N., Seitz A.E., Holland S.M., Prevots D.R. Prevalence of nontuberculous mycobacterial lung disease in U.S. medicare beneficiaries. Am J Respir Crit Care Med 2012, 185:881-886.
4. Moore J.E., Kruijshaar M.E., Ormerod L.P., Drobniewski F., Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010, 10:612.
5. Martín-Casabona N., Bahrmand A.R., Bennedsen J., Thomsen V.O., Curcio M., Fauville-Dufaux M., et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004, 8:1186-1193. Spanish Group for Non-Tuberculosis Mycobacteria.
6. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
7. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001, 56:167-172. Research Committee of the British Thoracic Society.
8. van Ingen J., Kuijper E.J. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol 2014, 9:1095-1110.
9. Tanaka E., Kimoto T., Tsuyuguchi K., Watanabe I., Matsumoto H., Niimi A., et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999, 160:866-872.
10. Kobashi Y., Yoshida K., Miyashita N., Niki Y., Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother Off J Japan Soc Chemother 2006, 12:195-202.
11. Griffith D.E., Brown-Elliott B.A., Langsjoen B., Zhang Y., Pan X., Girard W., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 174:928-934.
12. Kobashi Y., Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007, 74:394-400.
13. R Core Team R: a language and environment for statistical computing 2014, R Foundation for Statistical Computing, Vienna, Austria.
14. Wickham H. ggplot2: elegant graphics for data analysis 2009, Springer, New York.
15. Russell C.D., Claxton P., Doig C., Seagar A.-L., Rayner A., Laurenson I.F. Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2014, 69:593-595.
16. Lim H.-J., Park C.M., Park Y.S., Lee J., Lee S.-M., Yang S.-C., et al. Isolation of multiple nontuberculous mycobacteria species in the same patients. Int J Infect Dis 2011, 15:e795-e798.
17. Clark J., Thomson D.S., Wallace A. Disseminated infection with Mycobacterium avium: II. Bacteriology and drug susceptibility. Tubercle 1968, 49:31-37.
18. Woodley C.L., Kilburn J.O., David H.L., Silcox V.A. Susceptibility of mycobacteria to rifampin. Antimicrob Agents Chemother 1972, 2:245-249.
19. Rosenzweig D.Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979, 75:115-119.
20. Etzkorn E.T., Aldarondo S., McAllister C.K., Matthews J., Ognibene A.J. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 1986, 134:442-445.
21. Pezzia W., Raleigh J.W., Bailey M.C., Toth E.A., Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981, 3:1035-1039.
22. Richard J., Wallace J., Dunbar D., Brown B.A., Onyi G., Dunlap R., et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994, 18:736-743.
23. Chaisson R.E., Benson C.A., Dube M.P., Heifets L.B., Korvick J.A., Elkin S., et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994, 121:905-911.
24. Dautzenberg B. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995, 107:1035.
25. Wallace R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T., Onyi G.O., et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994, 149:1335-1341.
26. Wallace R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996, 153:1766-1772.
27. Jeon K., Kwon O.J., Lee N.Y., Kim B.-J., Kook Y.-H., Lee S.-H., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896-902.
28. Brown-Elliott B.A., Iakhiaeva E., Griffith D.E., Woods G.L., Stout J.E., Wolfe C.R., et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013, 51:3389-3394.
29. Clinical Laboratory Standards Institute Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes (CLSI document M24-A2) 2011, Clinical Standards Institute, PA, USA. 2nd ed.
30. Broda A., Jebbari H., Beaton K., Mitchell S., Drobniewski F. Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol 2013, 51:217-223.
31. Brown B.A., Wallace R.J., Onyi G.O. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992, 36:1987-1990.
32. da Silva Telles M.A., Chimara E., Ferrazoli L., Riley L.W. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005, 54:975-979.
33. Guna R., Muñoz C., Domínguez V., García-García A., Gálvez J., de Julián-Ortiz J.-V., et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005, 55:950-953.
34. Rodriguez Díaz J.C., Lopez M., Ruiz M., Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003, 21:585-588.
35. Swenson J.M., Wallace R.J., Silcox V.A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985, 28:807-811.
36. Wallace R.J., Nash D.R., Steele L.C., Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986, 24:976-981.
37. Huang Y.-C., Liu M.-F., Shen G.-H., Lin C.-F., Kao C.-C., Liu P.-Y., et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010, 43:401-406.
38. Ahmed I., Jabeen K., Hasan R. Identification of non-tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital: a cross-sectional study. BMC Infect Dis 2013, 13:493.
39. van Ingen J., van der Laan T., Dekhuijzen R., Boeree M., van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010, 35:169-173.
40. Hombach M., Somoskövi A., Hömke R., Ritter C., Böttger E.C. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. Int J Med Microbiol 2013, 303:270-276.
41. Lucke K., Hombach M., Friedel U., Ritter C., Böttger E.C. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST. J Antimicrob Chemother 2012, 67:154-158.
42. Jenkins P.A., Campbell I.A., Banks J., Gelder C.M., Prescott R.J., Smith A.P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008, 63:627-634.
43. Field S.K., Cowie R.L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003, 124:1482-1486.
44. van Ingen J., Totten S.E., Helstrom N.K., Heifets L.B., Boeree M.J., Daley C.L. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012, 56:6324-6327.
45. Wallace R.J., Dukart G., Brown-Elliott B.A., Griffith D.E., Scerpella E.G., Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014, 69:1945-1953.
46. Wallace R.J., Brown-Elliott B.A., Ward S.C., Crist C.J., Mann L.B., Wilson R.W. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45:764-767.